Core Viewpoint - The capital operations of Beilu Pharmaceutical, involving significant shareholder sell-offs and a planned private placement, raise questions about the underlying logic and potential market implications [1][2][3] Group 1: Shareholder Actions - Major shareholders, including Chongqing Three Gorges Paint Co., Ltd., have been actively reducing their stakes, with plans to sell up to 9.7 million shares, representing 1.98% of total shares [1] - From March 25 to June 19, 2025, Chongqing Three Gorges Paint reduced its holdings by 2.9988 million shares, decreasing its ownership from 8.23% to 7.59%, resulting in approximately 22 million yuan in cash [1] - The actual controller, Wang Daixue, also sold 7.3783 million shares in July 2025 for nearly 60 million yuan, following a previous sale of 9.7893 million shares in 2023 for over 66 million yuan [2] Group 2: Private Placement Details - Beilu Pharmaceutical announced plans to raise up to 300 million yuan through a simplified procedure for a private placement, aimed at funding the construction of a pharmaceutical production workshop and upgrading raw material production lines [1] - The pricing for the private placement has not been finalized but will be set at no less than 80% of the average price over the 20 trading days prior to the issuance date, raising concerns about potential arbitrage opportunities if the placement price is lower than the recent sell-off prices [2] - Historical context shows that in 2015, Beilu's private placement price was 12.9 yuan per share, while the market price remained above 15 yuan, leading to significant unrealized gains for participating shareholders [2]

中国经济网北京9月29日讯北陆药业（300016）(300016.SZ)昨日披露2025年度以简易程序向特定对象发 行股票预案，本次以简易程序向特定对象发行股票的募集资金总额不超过30,000.00万元(含本数)，扣除 相关发行费用后的募集资金净额将全部投资于"陆芝葆化药生产车间与智能综合仓库项目""新建100吨碘 美普尔、50吨碘比醇原料药生产线技改项目""补充流动资金"。 北陆药业表示，本次以简易程序向特定对象发行股票相关事项已由公司2024年年度股东大会根据《公司 章程》授权董事会决定以简易程序向特定对象发行融资总额人民币不超过三亿元且不超过最近一年末净 资产百分之二十的股票。根据公司2024年年度股东大会的批准和授权，本次发行相关事项已经获得公司 第九届董事会第四次会议审议通过，尚需经深圳证券交易所审核通过和中国证监会同意注册后方可实 施。 北陆药业本次以简易程序向特定对象发行股票的发行对象不超过35名(含35名)，为符合中国证监会规定 的证券投资基金管理公司、证券公司、信托投资公司、财务公司、保险机构投资者、合格境外机构投资 者及人民币合格境外机构投资者，以及符合中国证监会规定的其他法人、自然人或其 ...

Group 1 - Baiyun Airport announces joint investment with China Duty Free Group to establish a duty-free company with a registered capital of 45 million yuan, where China Duty Free Group holds 51% [3] - Dongxing Medical plans to acquire 90% stake in Wuhan Yijiaobao, a high-tech company focused on orthopedic and biomedical materials [4] - Fosun Pharma's subsidiary plans to transfer 100% stake in Shanghai Clone to enhance asset operation efficiency, with a transaction value of up to 1.256 billion yuan [5] Group 2 - Hengxing Technology's subsidiary is awaiting approval for the extension of mining license for Longtoushan Gold Mine, with exploration activities ongoing [6] - New Sai Co. announces resignation of its general manager Chen Jianjiang due to work adjustments [7] - Hailiang Co. is planning to issue H-shares and list on the Hong Kong Stock Exchange, with details yet to be finalized [8] Group 3 - Zhejiang University Network plans to sell 48.6 million shares of Wanliyang, expecting a transaction amount of 475 million yuan [9] - Huazhong Precision terminates the issuance of A-shares to specific targets, affecting a control acquisition [10] - Jiaze New Energy states that its green chemical business is not yet commercially viable, with no significant impact on revenue or profit in the short term [11] Group 4 - Hailan Home plans to issue H-shares and list on the Hong Kong Stock Exchange, with discussions ongoing with intermediaries [12] - Hongfuhang intends to invest up to 1.128 billion yuan in a joint venture to build a photovoltaic energy storage project in Congo [13] - Zhongchuang Zhiling plans to invest 5 billion yuan in a new energy vehicle parts industrial base and R&D center [14] Group 5 - Haitai Development's subsidiary signs a property sale contract worth 440 million yuan, expected to increase profits by approximately 62.86 million yuan in 2025 [15] - Dongjie Intelligent's overseas subsidiary secures a procurement order worth approximately 180 million yuan, representing 22.3% of its audited revenue for 2024 [17] - Zhiguang Electric's subsidiary signs a procurement contract worth 164 million yuan for energy storage systems [18] Group 6 - ST Songfa's subsidiary signs a shipbuilding contract for four VLCCs, with a contract value between 400 million to 600 million USD [19] - Huaguang Huaneng signs a sales contract for waste heat boilers worth 160 million yuan for a power plant project in Cambodia [20] - Yousheng Co. receives a project notification from a German automaker, with total sales expected to reach approximately 2.3 billion yuan [24] Group 7 - Zai Sheng Technology's controlling shareholder plans to reduce holdings by up to 3% [25] - Compton plans to reduce holdings of repurchased shares by up to 1% [26] - Aored plans to reduce holdings of repurchased shares by up to 1.29% [27] Group 8 - Xianhe Co. plans to raise up to 3 billion yuan through a private placement for a new materials project [34] - Guanshi Technology plans to raise up to 700 million yuan for photomask manufacturing and other projects [33] - Beilu Pharmaceutical plans to raise up to 300 million yuan for production facility upgrades and working capital [34]

Major Events - Baiyun Airport announced a joint investment with China Duty Free Group to establish a duty-free company at Guangzhou Baiyun Airport with a registered capital of 45 million yuan, where China Duty Free will contribute 22.95 million yuan for a 51% stake [4] - Dongxing Medical plans to acquire 90% of Wuhan Yijiaobao's equity for cash, which is expected to constitute a major asset restructuring [5] - Fosun Pharma's subsidiary is planning to transfer 100% of Shanghai Clon to enhance asset operation efficiency, with a transaction value of up to 1.256 billion yuan [7] - Hengxing Technology's subsidiary is undergoing a review for the extension of mining license for Longtoushan Gold Mine, with exploration activities ongoing [8] - New Sai Co.'s general manager Chen Jianjiang resigned due to work adjustments [9] - Hailiang Co. is planning to issue H-shares and list on the Hong Kong Stock Exchange, with details yet to be finalized [10] - Zhejiang University Net announced plans to sell 48.6 million shares of Wanliyang, expecting a transaction amount of 475 million yuan [11] - Huazhong Precision terminated its plan to issue A-shares to specific investors, which also halts the acquisition of control by a third party [12] - Jiazhe New Energy stated that its green chemical business is not yet commercially viable [13] Significant Contracts - Haitai Development's subsidiary signed a property sale contract worth 440 million yuan, expected to increase profits by approximately 62.86 million yuan in 2025 [18] - Dongjie Intelligent's overseas subsidiary received a procurement order worth approximately 180 million yuan, accounting for 22.3% of the company's audited revenue for 2024 [19][20] - Zhiguang Electric's subsidiary signed a procurement contract worth 164 million yuan for energy storage systems [21] - ST Songfa's subsidiary signed contracts for building four oil tankers, with a total value between 400 million to 600 million USD [22] - Huaguang Huaneng signed a sales contract for waste heat boilers worth 160 million yuan for a power plant project in Cambodia [23] - Keda Intelligent plans to issue H-shares and list on the Hong Kong Stock Exchange, with details still under discussion [24] Shareholding Changes - Zai Sheng Technology's controlling shareholder plans to reduce holdings by up to 3% [28] - Compton plans to reduce up to 1% of its repurchased shares [29] - Aorede plans to reduce up to 1.29% of its shares from the repurchased stock [30] - Yidian Tianxia's controlling shareholder plans to reduce up to 3% of its shares [31] - Huace Film's shareholders plan to transfer 3.6% of the company's shares through an inquiry transfer [32] Buybacks and Financing - Qibin Group obtained a special financing support of up to 90 million yuan for share repurchase [33] - CanSino plans to cancel 406,100 repurchased shares and reduce registered capital accordingly [35] Fundraising Initiatives - Xianhe Co. plans to raise up to 3 billion yuan through a private placement for a high-performance paper-based new materials project [36] - Guanshi Technology plans to raise up to 700 million yuan for photomask manufacturing and other projects [37] - Beilu Pharmaceutical plans to raise up to 300 million yuan for production line upgrades and working capital [38]

Core Viewpoint - Beilu Pharmaceutical (300016.SZ) plans to raise a total of no more than 300 million yuan through a simplified procedure for issuing shares to specific targets, which does not exceed 20% of the company's net assets at the end of the last fiscal year [1] Fundraising Details - The total amount of funds raised will not exceed 300 million yuan, including the principal amount [1] - The net proceeds from the fundraising, after deducting related issuance costs, will be fully invested in the construction of the Luzhibao chemical drug production workshop and intelligent comprehensive warehouse project, as well as the technical transformation project for a new 100-ton iodinated methyl propyl and 50-ton iodinated butanol raw material production line, and to supplement working capital [1]

Group 1 - North Lu Pharmaceutical announced a stock issuance plan approved by the 2024 annual general meeting, aiming to raise no more than 300 million yuan [1] - The stock issuance will target no more than 35 specific investors, with the issuance price set at no less than 80% of the average trading price over the previous 20 trading days [1] - The raised funds will be allocated to three main projects: approximately 234 million yuan for the construction of a pharmaceutical production workshop and smart warehouse, 39.86 million yuan for the renovation of a new production line for iodine-based raw materials, and 26.4 million yuan for working capital [1] Group 2 - As of the latest report, North Lu Pharmaceutical has a market capitalization of 4.9 billion yuan [2] - The company's revenue composition for 2024 indicates that 98.88% of its income will come from pharmaceutical production, while other business revenues will account for 1.12% [1]

Core Viewpoint - Beilu Pharmaceutical (300016.SZ) plans to issue shares to specific targets through a simplified procedure, aiming to raise no more than 300 million yuan for various projects and working capital [1] Group 1: Share Issuance Details - The company intends to issue shares to no more than 35 specific targets [1] - The issuance price will not be lower than 80% of the average trading price of the company's shares over the 20 trading days prior to the pricing benchmark [1] - The total number of shares issued will be determined by the total amount of funds raised divided by the issuance price, not exceeding 30% of the company's total share capital before the issuance [1] Group 2: Fund Utilization - The total amount raised from the share issuance will not exceed 300 million yuan, including the principal [1] - After deducting related issuance costs, the net proceeds will be fully invested in the construction of the Luzhibao pharmaceutical production workshop and intelligent comprehensive warehouse project [1] - Additional investments will be made in the technical transformation project for a new 100-ton iodinated methylpyrrolidone and 50-ton iodinated butanol raw material production line, as well as to supplement working capital [1]

股票代码：300016 股票简称：北陆药业 公告编号：2025-098 北京北陆药业股份有限公司 关于 2025 年度以简易程序向特定对象发行股票预案披露的 提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 北京北陆药业股份有限公司（以下简称"公司"）于 2025 年 9 月 25 日召开第九届董 事会第四次会议，审议通过了关于公司 2025 年度以简易程序向特定对象发行股票的相关议 案。《北京北陆药业股份有限公司 2025 年度以简易程序向特定对象发行股票预案》（以下简 称"预案"）已于 2025 年 9 月 27 日在中国证监会指定的创业板信息披露网站巨潮资讯网 （http://www.cninfo.com.cn）上进行披露，敬请投资者注意查阅。 本次预案的披露不代表审批机关对于本次以简易程序向特定对象发行股票相关事项的 实质性判断、确认、批准或注册。本次预案所述以简易程序向特定对象发行股票相关事项 的生效和完成尚待有关审批机关的批准或核准。敬请广大投资者注意投资风险。 特此公告。 北京北陆药业股份有限公司 董事会 二○二五年九月二十七日 ...

公司声明 一、本公司及董事会全体成员保证本预案内容真实、准确、完整，确认不存在虚假记 载、误导性陈述或重大遗漏，并对本预案内容的真实性、准确性、完整性承担个别和连带 的法律责任。 二、本预案按照《中华人民共和国公司法》《中华人民共和国证券法》《上市公司证券 发行注册管理办法》等要求编制。 北京北陆药业股份有限公司 BEIJING BEILU PHARMACEUTICAL CO.,LTD. 2025 年度以简易程序向特定 对象发行股票预案 股票代码：300016 股票简称：北陆药业 披露日期：2025.09 2025 年度以简易程序向特定对象发行股票预案 三、本次以简易程序向特定对象发行股票完成后，公司经营与收益的变化，由公司自 行负责；因本次以简易程序向特定对象发行股票引致的投资风险，由投资者自行负责。 四、本预案是公司董事会对本次以简易程序向特定对象发行股票的说明，任何与之相 反的声明均属不实陈述。 五、投资者如有任何疑问，应咨询自己的股票经纪人、律师、专业会计师或其他专业 顾问。 六、本预案中如有涉及投资效益或业绩预测等内容，均不构成公司对任何投资者及相 关人士的承诺，投资者及相关人士应当理解计划、预测与 ...

北京北陆药业股份有限公司 BEIJING BEILU PHARMACEUTICAL CO.,LTD. 2025年度以简易程序向特定 对象发行股票方案 论证分析报告 股票代码：300016 股票简称：北陆药业 披露日期：2025.09 北京北陆药业股份有限公司（以下简称"北陆药业"或"公司"）是在深圳证券交易 所创业板上市的公司，为满足公司业务发展的资金需求，增强公司资本实力和行业竞争力， 根据《中国人民共和国公司法》《中华人民共和国证券法》《上市公司证券发行注册管理 办法》等规定，公司拟通过以简易程序向特定对象发行股票的方式募集资金不超过30,000.00 万元，用于陆芝葆化药生产车间与智能综合仓库项目、新建100吨碘美普尔、50吨碘比醇原 料药生产线技改项目并补充流动资金。 本报告中如无特别说明，相关用语与《北京北陆药业股份有限公司2025年度以简易程 序向特定对象发行股票预案》中的释义具有相同含义。 一、本次发行的背景和目的 （一）本次发行的背景 1、国家政策鼓励化药行业发展，同时对药品仓储及流通要求提高 报告期内，公司以成为"中国医药制造百强企业"为中长期发展目标，践行"化药+ 中药"双轮驱动的业务模式 ...